Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 25 articles:
HTML format



Single Articles


    March 2022
  1. FUKUDA N, Akamine Y, Abumiya M, Takahashi S, et al
    Relationship between achievement of major molecular response or deep molecular response and nilotinib plasma concentration in patients with chronic myeloid leukemia receiving first-line nilotinib therapy.
    Cancer Chemother Pharmacol. 2022 Mar 22. pii: 10.1007/s00280-022-04419.
    PubMed     Abstract available


    February 2022
  2. RAMALINGAM R, Kaur H, Scott JX, Sneha LM, et al
    Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients.
    Cancer Chemother Pharmacol. 2022 Feb 14. pii: 10.1007/s00280-022-04405.
    PubMed     Abstract available


    January 2022
  3. LIU J, Luo W, Chen Q, Chen X, et al
    Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota.
    Cancer Chemother Pharmacol. 2022 Jan 23. pii: 10.1007/s00280-021-04385.
    PubMed     Abstract available


    November 2021
  4. YOSHIDA K, Fujita A, Narazaki H, Asano T, et al
    Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
    Cancer Chemother Pharmacol. 2021 Nov 26. pii: 10.1007/s00280-021-04373.
    PubMed     Abstract available


  5. TONG WH
    Comment on "Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase".
    Cancer Chemother Pharmacol. 2021;88:919-920.
    PubMed    


    October 2021
  6. PANETTA JC, Liu Y, Bottiglieri T, Arning E, et al
    Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
    Cancer Chemother Pharmacol. 2021;88:655-664.
    PubMed     Abstract available


    September 2021
  7. CONDORELLI A, Matteo C, Leotta S, Schinina G, et al
    Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomeningeal involvement.
    Cancer Chemother Pharmacol. 2021 Sep 29. pii: 10.1007/s00280-021-04356.
    PubMed     Abstract available


    July 2021
  8. GOTO H, Yoshino Y, Ito M, Nagai J, et al
    Correction to: Aurora B kinase as a therapeutic target in acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2021 Jul 18. pii: 10.1007/s00280-021-04321.
    PubMed    


    June 2021
  9. TOKSVANG LN, Andres-Jensen L, Rank CU, Niinimaki R, et al
    Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Cancer Chemother Pharmacol. 2021 Jun 18. pii: 10.1007/s00280-021-04316.
    PubMed     Abstract available


    May 2021
  10. YOUSSEF YH, Makkeyah SM, Soliman AF, Meky NH, et al
    Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2021 May 7. pii: 10.1007/s00280-021-04290.
    PubMed     Abstract available


    April 2021
  11. NIELSEN SN, Toksvang LN, Grell K, Nersting J, et al
    No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
    Cancer Chemother Pharmacol. 2021 Apr 29. pii: 10.1007/s00280-021-04281.
    PubMed     Abstract available


    March 2021
  12. LARSEN RH, Hjalgrim LL, Degn M, Nersting J, et al
    Dynamics of leucocyte DNA thioguanine nucleotide levels during maintenance therapy of childhood acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2021 Mar 23. pii: 10.1007/s00280-020-04219.
    PubMed     Abstract available


  13. KASHANIAN SM, Holtzman NG, Patzke CL, Cornu J, et al
    Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
    Cancer Chemother Pharmacol. 2021 Mar 7. pii: 10.1007/s00280-021-04252.
    PubMed     Abstract available


    January 2021
  14. KANG D, Ludwig E, Jaworowicz D, Huang H, et al
    Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2021 Jan 8. pii: 10.1007/s00280-020-04204.
    PubMed     Abstract available


    November 2020
  15. AL-SHEIKH A, Yousef AM, Alshamaseen D, Farhad R, et al
    Effects of thymidylate synthase polymorphisms on toxicities associated with high-dose methotrexate in childhood acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2020 Nov 10. pii: 10.1007/s00280-020-04197.
    PubMed     Abstract available


    October 2020
  16. LATOCH E, Kononczuk K, Taranta-Janusz K, Muszynska-Roslan K, et al
    Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors.
    Cancer Chemother Pharmacol. 2020 Oct 14. pii: 10.1007/s00280-020-04164.
    PubMed     Abstract available


    September 2020
  17. ABBARA C, Drevin G, Ferec S, Ghamrawi S, et al
    Slower degradation rate of cytarabine in blood samples from acute myeloid leukemia by comparison with control samples.
    Cancer Chemother Pharmacol. 2020 Sep 29. pii: 10.1007/s00280-020-04150.
    PubMed     Abstract available


  18. PRAKASH C, Fan B, Ke A, Le K, et al
    Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2020 Sep 25. pii: 10.1007/s00280-020-04148.
    PubMed     Abstract available


  19. LIN S, Shaik N, Chan G, Cortes JE, et al
    An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure.
    Cancer Chemother Pharmacol. 2020 Sep 3. pii: 10.1007/s00280-020-04132.
    PubMed     Abstract available


  20. LUCAFO M, Sicari D, Chicco A, Curci D, et al
    miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway.
    Cancer Chemother Pharmacol. 2020;86:361-374.
    PubMed     Abstract available


    August 2020
  21. ELMELIEGY M, Den Haese J, Talati C, Wetzler M, et al
    Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2020 Aug 3. pii: 10.1007/s00280-020-04114.
    PubMed     Abstract available


    July 2020
  22. ZHANG H, Xu H, Zhang R, Zhao X, et al
    Chemosensitization by 4-hydroxyphenyl retinamide-induced NF-kappaB inhibition in acute myeloid leukemia cells.
    Cancer Chemother Pharmacol. 2020 Jul 21. pii: 10.1007/s00280-020-04115.
    PubMed     Abstract available


    June 2020
  23. LARSEN RH, Hjalgrim LL, Grell K, Kristensen K, et al
    Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
    Cancer Chemother Pharmacol. 2020 Jun 9. pii: 10.1007/s00280-020-04097.
    PubMed     Abstract available


    May 2020
  24. FAN B, Dai D, DiNardo CD, Stein E, et al
    Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
    Cancer Chemother Pharmacol. 2020;85:959-968.
    PubMed     Abstract available


    April 2020
  25. LIU X, Jiang Y, Nowak B, Ichikawa S, et al
    Repair of DNA damage induced by the novel nucleoside analogue CNDAG through homologous recombination.
    Cancer Chemother Pharmacol. 2020;85:661-672.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: